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Abstract
A 66-year-old man with HIV and recurrent thromboembolism presented with new-onset ascites with an extensive 
diagnostic work-up that was unremarkable. He was diagnosed with non-cirrhotic portal hypertension after a liver 
biopsy revealed mild fibrosis and hepatic venography revealed an elevated hepatic venous pressure gradient. 
The etiology of portal hypertension was attributed to didanosine therapy, a rare but noted side effect.  
Introduction
Portal hypertension is typically attributed to the presence of underlying cirrhosis, though, in rare cases, may re-
sult from alternate pathologies. This phenomenon, known as non-cirrhotic portal hypertension (NCPH) can arise 
from idiopathic portal hypertension, extrahepatic portal venous thrombosis, schistosomiasis, veno-occlusive dis-
ease, and congenital hepatic fibrosis. 
Case Report
A 66-year-old white man with HIV, on treatment for 20 years, presented with several months of progressive 
abdominal distention and early satiety. He suffered from recurrent deep venous thromboembolism and pulmo-
nary embolism for which an inferior vena cava (IVC) filter had been placed. His medications included tenofovir, 
didanosine, and nevirapine for several years, and chronic anticoagulation with coumadin. He had no significant 
alcohol use.  
His examination showed a protuberant abdomen with a fluid wave, shifting dullness, and a palpable spleen. 
Laboratory values revealed normal electrolytes, renal function, hemoglobin, and white blood cell count. His 
platelet count was 110,000 U/mL. His hepatic panel revealed an alanine aminotransferase (ALT) 24 U/L, aspar-
tate aminotransferase (AST) 43 U/L, bilirubin 0.4 mg/dL, alkaline phosphatase 157 U/L, total protein 5.9 g/dL, 
and albumin 3.3 g/dL. His international normalized ratio (INR) was 1.8 (on coumadin therapy). His CD4 count 
was 278 cells per mm3 and HIV viral load was undetectable.
A Doppler ultrasound and abdominal computed tomography (CT) revealed ascites, but was otherwise normal. A 
diagnostic paracentesis revealed a serum ascites–albumin gradient of 1.5 g/dL with a total protein of 2.7 g/dL. Chest 
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radiograph and echocardiogram were normal. A chronic liver 
disease work-up was negative, including hepatitis B surface 
antigen, hepatitis B surface antibody, hepatitis B core anti-
body, anti-hepatitis C virus antibody, antinuclear antibody, 
anti-mitochondrial antibody, anti-smooth muscle antibody, 
iron studies, α-1 antitryspin phenotype, and ceruloplasmin. 
Stool examination did not show evidence of schistosomiasis. 
Acid-fast bacilli culture and smear of the peritoneal fluid and 
quantiferon-gold testing was negative.  
A transjugular liver biopsy revealed a hepatic wedge pres-
sure of 26 mm Hg, free hepatic vein pressure of 12 mm 
Hg, hepatic venous pressure gradient (HVPG) of 14 mm Hg, 
and mild perisinusoidal fibrosis without bridging fibrosis, 
confirming the diagnosis of NCPH (Figure 1).
Discussion
In the United States, cirrhosis accounts for 85% of cases 
of ascites.1 Multiple etiologies, including heart failure, 
peritoneal carcinomatosis, nephrotic syndrome, tuber-
culosis peritonitis, and Budd-Chiari syndrome, comprise 
the remaining 15%, with NCPH being quite uncommon. 
This case was unique given the variety of risk factors that 
made alternative etiologies of ascites possible (i.e., his-
tory of recurrent blood clots, presence of IVC filter, and 
history of HIV). To confirm NCPH, one must have clinical 
signs of portal hypertension with patent hepatic vascula-
ture on imaging, the exclusion of cirrhosis on biopsy, and 
exclusion of other causes of liver disease on laboratory 
work-up.2 
Didanosine is an antiretroviral agent frequently used 
as part of highly active antiretroviral therapy (HAART). 
NCPH is an increasingly seen complication associated 
with didanosine exposure,3-6 which has led the Food and 
Drug Administration to update the labeling of the drug. 
While the mechanism by which didanosine causes NCPH 
is not known, it may be caused by depletion of intracellu-
lar glutathione with subsequent death of sinusoidal endo-
thelial cells. A potential genetic predisposition and causal 
effect of duration of didanosine therapy have been impli-
cated in its pathogenesis. A large case-control study per-
formed in the Netherlands has implicated tenofovir when 
issued concomitantly with didanosine to an increased risk 
of NCPH.4 Management involves cessation of the caus-
ative drug and treatment of portal hypertension-related 
sequela.5-6
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Figure 1. Liver biopsy with portal hypertension. Histology with trichrome 
staining revealed mild fibrosis (seen in blue) around the edges of the portal 
tracts, without evidence of bridging fibrosis or cirrhosis.
